Welcome to our dedicated page for Defence Therapeu news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on Defence Therapeu stock.
Defence Therapeutics Inc. reports developments in biotechnology and precision intracellular drug delivery through its proprietary Accum® platform. Company news centers on cancer-therapy applications, including antibody-drug conjugates, radiopharmaceutical and radio-immunoconjugate programs, and other complex biologics designed for intracellular and nuclear delivery.
Recurring updates also cover scientific advisory activity, industry presentations, collaboration work such as its program with Canadian Nuclear Laboratories, partnership outreach, and capital-structure actions including private placements, warrant amendments, and restricted stock unit grants.
Defence Therapeutics (OTCQB:DTCFF) launched a private placement of up to 20,000,000 Units at $0.55 for aggregate gross proceeds up to $11,000,000. Each Unit includes one share and one warrant exercisable at $0.65 for 24 months.
The company executed a binding term sheet for $6,000,000 CAD from two institutional investors with proceeds held in escrow and released as monthly cash tranches of $333,333 CAD over 18 months, subject to a sharing agreement that ties monthly share releases to a $0.7332 CAD benchmark price.
Defence Therapeutics (OTCQB: DTCFF) convened a Scientific Advisory Board on January 30, 2026 to align its Accum ADC strategy for improved intracellular payload delivery. Advisors with ADC chemistry, translational science, and partnering expertise informed prioritization of key experiments, data alignment for future clinical translation, and partnering readiness.
The SAB feedback is guiding a refined Accum ADC development roadmap aimed at enabling more effective, better-tolerated ADC therapies and positioning the platform for strategic collaborations.
Defence Therapeutics (OTCQB: DTCFF) will present at World ADC Europe 2026 in London, February 23–26, 2026, showcasing its proprietary Accum intracellular drug‑delivery platform.
The company said it will use the forum to engage potential partners, discuss co‑development of Accum‑enabled ADCs and precision oncology biologics, and schedule partnering meetings.
Defence Therapeutics (OTCQB:DTCFF) deepened its collaboration with Canadian Nuclear Laboratories to accelerate its proprietary radiopharmaceutical pipeline. The expanded partnership will initiate multiple radioisotope programs using Defence's Accum platform as lead program data aim to support candidate selection and prepare for first-in-human studies.
The move positions Defence to broaden radiopharmaceutical assets alongside its ADC work and leverage CNL nuclear science expertise to advance programs toward the clinic.
Defence Therapeutics (OTCQB: DTCFF) said it is repositioning as a precision intracellular drug-delivery company centered on its proprietary Accum platform.
The company says Accum enhances cellular uptake and payload release to boost therapeutic potency at lower doses and potentially reduce toxicity. Defence plans a dual strategy of internal R&D plus strategic partnerships to apply Accum to antibody-drug conjugates, radiopharmaceuticals and other complex biologics, with the stated goal of enabling safer, earlier-line cancer treatments and creating scalable value for partners and shareholders.
Defence Therapeutics (OTCQB: DTCFF) reported results from its December 10, 2025 annual meeting and provided corporate updates.
Shareholders approved a five-member board and ratified Crowe MacKay as auditors. The company granted 800,000 stock options exercisable at $0.82 for 10 years. Defence amended 967,000 warrants from private placements, extending expiry by 12 months and repricing exercise price from $2.00 to $1.00 (new expiries Jan 30, 2027 and Mar 22, 2027).
Defence disclosed a marketing services agreement with i2i Marketing Group for USD $300,000, starting ~Nov 3, 2025, with $50,000 paid on signing and remaining payments tied to completion conditions.
Defence Therapeutics (OTCQB: DTCFF) announced formation of its inaugural Scientific Advisory Board (SAB) on December 4, 2025, appointing Rob Leanna, Danny Chui, and Brendan Hussey.
The company said its Accum®-enhanced ADC program reached laboratory validations showing increased intracellular accumulation and improved efficacy for Accum-enhanced ADCs. The SAB will provide scientific, technical, and strategic guidance across CMC, antibody engineering, preclinical pharmacology, translational biology, and partnering to support progression toward clinical development and scale.
Defence Therapeutics (OTCQB:DTCFF) announced that holders of its 8% convertible debentures issued November 16, 2024, converted all principal and accrued interest into common shares upon maturity on November 16, 2025.
The principal amount of $1,476,000 converted into 2,460,000 shares at a conversion price of $0.60 per share, and $118,080 of accrued interest converted into 147,600 shares at $0.80 per share, totalling 2,607,600 shares and an aggregate amount of $1,594,080.
Defence Therapeutics (OTCQB: DTCFF) announced a strategic shift to supply its proprietary Accum drug‑delivery platform to antibody‑drug conjugate (ADC) developers after presenting at the World ADC Conference and CPHI.
Defence reported completed preclinical studies showing Accum‑conjugated Kadcyla produced ~20‑fold higher anti‑tumor efficacy than Kadcyla alone at the same 0.5 mg/kg dose in JIMT‑1 HER2+ mouse xenografts, with a near‑complete response in 90% of mice.
The company is engaging ADC partners to license or supply Accum for improving potency and reducing toxicity across ADC programs.
Defence Therapeutics (OTCQB:DTCFF) presented new preclinical data on its proprietary Accum platform at the 16th World ADC Conference in San Diego (November 4-5, 2025).
Presenters said Accum enhanced intracellular delivery and payload release in ADCs, improving potency and therapeutic index in the data shown. Defence announced plans to expand collaborative and internal testing of Accum across multiple commercial and clinical-stage ADC constructs to evaluate plug-and-play applicability across different antibodies and payloads.
The company indicated active engagement with industry partners to accelerate evaluations and explore potential benefits for targeted cancer therapies.